49. Infectious Risks Associated with Anti-Thymocyte Globulin (ATG, Thymoglobulin)

  1. Deepali Kumar MD, MSc, FRCPC and
  2. Atul Humar MD, MSc, FRCPC
  1. Steven D. Burdette MD, FIDSA

Published Online: 5 MAY 2011

DOI: 10.1002/9781444397949.ch49

The AST Handbook of Transplant Infections

The AST Handbook of Transplant Infections

How to Cite

Burdette, S. D. (2011) Infectious Risks Associated with Anti-Thymocyte Globulin (ATG, Thymoglobulin), in The AST Handbook of Transplant Infections (eds D. Kumar and A. Humar), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444397949.ch49

Editor Information

  1. Transplant Infectious Diseases, University of Alberta, Edmonton, Canada

Author Information

  1. Infectious Diseases Fellowship, Miami Valley Hospital Transplant Program, WSU Boonshoft School of Medicine, Dayton, OH, USA

Publication History

  1. Published Online: 5 MAY 2011
  2. Published Print: 13 MAY 2011

ISBN Information

Print ISBN: 9780470658277

Online ISBN: 9781444397949

SEARCH

Keywords:

  • infectious risks associated with anti-thymocyte globulin (ATG, thymoglobulin);
  • mechanism of action - anti-thymocyte globulin (ATG), polyclonal antibody inducing dose-dependent depletion of T cells;
  • duration of effect - profound CD3 lymphopenia, lasting 1 year;
  • impact on laboratory monitoring;
  • impact on prophylaxis;
  • fungal infections - associated with false-positive Histoplasma urine antigens;
  • HCV/HBV - data lacking, progression of HBV infection associated with ATG;
  • pneumocystis - risk alleviated with proper prophylaxis;
  • HCV, hepatitis C virus;
  • IL-2R, interleukin-2R